According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...

Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...

After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...

A study of an urban US population reports a sharp decline in dermatologic disease in people with newly diagnosed HIV and ...

The matter came to light on Friday after the child's family accused the blood bank of transfusing HIV-infected blood to the ...